Loading...
•
Sep 30, 2022
Conmed Q3 2022 Earnings Report
Delivered strong top-line growth in a tougher-than-expected environment.
Key Takeaways
CONMED Corporation announced its Q3 2022 financial results, reporting strong top-line growth. The company narrowed its revenue guidance for the full year 2022 and now expects revenue between $1.1 billion and $1.115 billion. The Company now expects full-year 2022 adjusted diluted net earnings per share in the range of $3.21 to $3.28.
Third quarter results delivered strong top-line growth.
Closed on acquisition of Biorez during the quarter.
In2Bones and Biorez integrations are off to fantastic starts.
Confident that both businesses will add to future outlook of sustained growth in revenue and profitability.
Forward Guidance
The company is narrowing its revenue guidance for the full year 2022 and now expects revenue between $1.1 billion and $1.115 billion compared to its prior guidance of between $1.095 billion and $1.140 billion. The Company now expects full-year 2022 adjusted diluted net earnings per share in the range of $3.21 to $3.28, down from the prior range of $3.25 to $3.45.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...